AcuityMD Lands $80 Million in New Funding 

AcuityMD today announced $80 million in new funding to elevate its platform with advanced artificial intelligence (AI) capabilities and accelerate medical technology adoption.

Existing investor StepStone Group led the Series C round, though additional financial support came from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management. Now supporting 16 of the top 20 medtech companies and having helped customers identify more than $34 billion in pipeline, AcuityMD has raised more than $160 million to date and is valued at $955 million.

“AcuityMD is scaling rapidly while continuing to invest thoughtfully in its people and platform,” StepStone Group Partner Hunter Somerville said. “The depth of the company’s data provides an advantage, and as AI capabilities continue to advance, that foundation becomes more valuable. We also see significant opportunities for AcuityMD to benefit the broader medtech organization beyond commercial, reinforcing our decision to deepen our commitment.”

Medtech companies face mounting pressure not only to successfully launch innovations, but also to capture and grow market share in an environment that can shift abruptly. Portfolio changes, hospital consolidation, regulatory fluctuation, and reimbursement updates can upend the competitive landscape faster than any sales representative or leader can track on their own.

AcuityMD executives say the company was built to solve the root cause of the problem: the commercial insights medtech firms need are scattered across claims databases, U.S. Food and Drug Administration filings, government records, and market signals that no single company can assemble alone. AcuityMD aggregates all of it into a proprietary medtech ontology: a continuously enriched knowledge graph mapping entities including physicians, facilities, networks, procedures, reimbursement dynamics, and the relationships between them. It aligns that ontology with each customer’s internal data, including contracting information, product indications, territory structure, and CRM activity. The result is a unified, continuously updated view of the healthcare market for faster, smarter commercial execution.

AcuityAI, now available in open beta, is the AI built on that foundation. It connects AcuityMD’s ontology, a company’s business context, and each rep’s specific situation to surface answers no horizontal AI platform can replicate. Reps spend less time figuring out where to go and more time in front of the right physicians, armed with the right context to win more business.

“AcuityAI has given our commercial team sharper answers, faster,” said Mark Edwards, senior director of sales operations at Kuros Biosciences. “Insights that used to take hours are now surfaced right when our reps need them, leading to richer conversations and opportunities we might otherwise have missed. One of our sales leaders asked AcuityAI for intel on a new national contract with a large health system and quickly had a full business plan: where to go, which surgeons to prioritize, and more context than he could get spending hours on Google.”

AcuityMD’s new capital will fund three priorities: accelerate agentic AI capabilities for commercial personas, including sales reps, leadership, and marketing teams; deepen the medtech ontology that powers AcuityMD’s data model; and expand the platform beyond commercial in pursuit of the company’s broader mission to accelerate medical technology adoption across the full product lifecycle.

“AI will transform medtech, but only with the right context, deeply embedded in the workflows where decisions are made. AcuityMD is that context layer, serving the rep in the field, the commercial leader planning territories, and the teams launching the next generation of innovation. I’m grateful to the hundreds of customers who have helped shape our platform,” AcuityMD Co-Founder/CEO Mike Monovoukas concluded. “This funding accelerates our shared mission of accelerating adoption of cutting-edge medical technologies.”

‍Commercial teams use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world healthcare data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate medical technology adoption. AcuityMD was named to Forbes’ 2025 “Next Billion-Dollar Startups” list—a group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation.‍